Developing precision treatments for epilepsy using patient and animal models

References

• Moshé SL, Perucca E, Ryvlin P, et al. Epilepsy: new advances. The Lancet. 2015;385(9971):884–898.
   PubMed Web of Science ®Google Scholar
• Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia. 2012;53(Suppl 8):26–39.
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010;19(10):650–655.
   PubMed Web of Science ®Google Scholar
• Barker-Haliski M, White HS. Validated animal models for antiseizure drug (ASD) discovery: advantages and potential pitfalls in ASD screening. Neuropharmacology. 2020;167:107750.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–319.
   PubMed Web of Science ®Google Scholar
• Löscher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016;126:157–184.
   PubMed Web of Science ®Google Scholar
• Pitkänen A, Engel J Jr. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics. 2014;11(2):231–241.
   PubMed Web of Science ®Google Scholar
• Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science. 1937;85(2213):525–526.
   PubMedGoogle Scholar
• Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6(9):793-804.
   PubMed Web of Science ®Google Scholar
• Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20(5):359–368.
   PubMed Web of Science ®Google Scholar
• Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993;232(2–3):147–158.
   PubMed Web of Science ®Google Scholar
• Perucca P, Scheffer IE, Kiley M. The management of epilepsy in children and adults. Med J Aust. 2018;208(5):226–233.
   PubMed Web of Science ®Google Scholar
• Krall RL, Penry JK, White BG, et al. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia. 1978;19(4):409–428.
   PubMed Web of Science ®Google Scholar
• Lukawski K, Gryta P, Luszczki J, et al. Exploring the latest avenues for antiepileptic drug discovery and development. Expert Opin Drug Discov. 2016;11(4):369–382.
   PubMed Web of Science ®Google Scholar
• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68–82.
   PubMed Web of Science ®Google Scholar
• Goddard GV. Development of epileptic seizures through brain stimulation at low intensity. Nature. 1967;214(5092):1020–1021.
   PubMed Web of Science ®Google Scholar
• Sato M, Racine RJ, McIntyre DC. Kindling: basic mechanisms and clinical validity. Electroencephalogr Clin Neurophysiol. 1990;76(5):459–472.
   PubMedGoogle Scholar
• Matagne A, Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 1998;31(1):59–71.
   PubMed Web of Science ®Google Scholar
• Rowley NM, White HS. Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models. Epilepsy Res. 2010;92(2–3):163–169.
   PubMed Web of Science ®Google Scholar
• Barker-Haliski M. How do we choose the appropriate animal model for antiseizure therapy development? Expert Opin Drug Discov. 2019;14(10):947–951.
   PubMed Web of Science ®Google Scholar
• Lason W, Dudra-Jastrzebska M, Rejdak K, et al. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep. 2011;63(2):271–292.
   PubMed Web of Science ®Google Scholar
• Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the seventh eilat conference (EILAT VII). Epilepsy Res. 2004;61(1–3):1–48.
   PubMed Web of Science ®Google Scholar
• Heaney D, Walker MC. Rufinamide. Drugs Today. 2007;43(7):455–460.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the ninth eilat conference (EILAT IX). Epilepsy Res. 2009;83(1):1–43.
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Trojnar MK, Gergont A, et al. Stiripentol – characteristic of a new antiepileptic drug. Expert Opin Drug Discov. 2008;3(4):453–460.
   PubMed Web of Science ®Google Scholar
• Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov. 2014;9(4):449–458.
   PubMed Web of Science ®Google Scholar
• Matagne A, Margineanu D-G, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154(8):1662–1671.
   PubMed Web of Science ®Google Scholar
• Stables JP, Bertram E, Dudek FE, et al. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia. 2003;44(12):1472–1478.
   PubMedGoogle Scholar
• Potschka H. Animal models of drug-resistant epilepsy. Epileptic Disord. 2012;14(3):226–234.
   PubMed Web of Science ®Google Scholar
• Barton ME, Klein BD, Wolf HH, et al. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47(3):217–227.
   PubMed Web of Science ®Google Scholar
• Leclercq K, Kaminski RM. Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model. Epilepsia. 2015;56(2):310–318.
   PubMed Web of Science ®Google Scholar
• Twele F, Töllner K, Bankstahl M, et al. The effects of carbamazepine in the intrahippocampal kainate model of temporal lobe epilepsy depend on seizure definition and mouse strain. Epilepsia Open. 2016;1(1–2):45–60.
   PubMedGoogle Scholar
• Riban V, Bouilleret V, Pham-Lê BT, et al. Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy. Neuroscience. 2002;112(1):101–111.
   PubMed Web of Science ®Google Scholar
• Postma T, Krupp E, Li XL, et al. Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. Epilepsia. 2000;41:1514–1521.
   PubMed Web of Science ®Google Scholar
• Srivastava AK, White HS. Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats. Epilepsy Res. 2013;104(1–2):26–34.
   PubMed Web of Science ®Google Scholar
• Löscher W, Klitgaard H, Twyman RE, et al. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12(10):757–776.
   PubMed Web of Science ®Google Scholar
• Löscher W, Brandt C, Sibley D. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharm Rev. 2010;62(4):668–700.
   PubMed Web of Science ®Google Scholar
• Mani R, Pollard J, Dichter MA. Human clinical trails in antiepileptogenesis. Neurosci Lett. 2011;497(3):251–256.
   PubMed Web of Science ®Google Scholar
• Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epileptic Disord. 2012;14(2):105–113.
   PubMed Web of Science ®Google Scholar
• Lukasiuk K. Epileptogenesis. In: Aminoff MJ, Daroff RB, editors. Encyclopedia of the neurological sciences. Second Edition ed. Oxford: Academic Press; 2014. p. 196–199.
   Google Scholar
• Pitkänen A, Kharatishvili I, Karhunen H, et al. Epileptogenesis in experimental models. Epilepsia. 2007;48(Suppl s2):13–20.
   PubMedGoogle Scholar
• Wang J, Lin Z-J, Liu L, et al. Epilepsy-associated genes. Seizure. 2017;44:11–20.
   PubMed Web of Science ®Google Scholar
• Nicita F, De Liso P, Danti FR, et al. The genetics of monogenic idiopathic epilepsies and epileptic encephalopathies. Seizure. 2012;21(1):3–11.
   PubMed Web of Science ®Google Scholar
• Wagnon JL, Korn MJ, Parent R, et al. Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy. Hum Mol Genet. 2015;24(2):506–515.
   PubMed Web of Science ®Google Scholar
• Salmi M, Bolbos R, Bauer S, et al. Transient microstructural brain anomalies and epileptiform discharges in mice defective for epilepsy and language-related NMDA receptor subunit gene Grin2a. Epilepsia. 2018;59(10):1919–1930.
   PubMed Web of Science ®Google Scholar
• Jozwiak S, Kotulska K, Wong M, et al. Modifying genetic epilepsies – results from studies on tuberous sclerosis complex. Neuropharmacology. 2020;166:107908.
   PubMed Web of Science ®Google Scholar
• Uhlmann EJ, Wong M, Baldwin RL, et al. Astrocyte-specificTSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol. 2002;52(3):285–296.
   PubMed Web of Science ®Google Scholar
• White HS, Löscher W. Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. Neurotherapeutics. 2014;11(2):373–384.
   PubMed Web of Science ®Google Scholar
• Helbig I, Ellis CA. Personalized medicine in genetic epilepsies – possibilities, challenges, and new frontiers. Neuropharmacology. 2020;172:107970.
   PubMed Web of Science ®Google Scholar
• Maheshwari A, Noebels JL. Monogenic models of absence epilepsy: windows into the complex balance between inhibition and excitation in thalamocortical microcircuits. Prog Brain Res. 2014;213:223–252.
   PubMed Web of Science ®Google Scholar
• French JA, Faught E. Rational polytherapy. Epilepsia. 2009;50(Suppl 8):63–68.
   PubMed Web of Science ®Google Scholar
• Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41(11):1364–1374.
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia. 2004;45(8):895–907.
   PubMed Web of Science ®Google Scholar
• Tallarida RJ. Drug Combinations: tests and Analysis with Isoboles. Curr Protoc Pharmacol. 2016;72(1):9.19.1–9.19.19.
   PubMedGoogle Scholar
• Rowan AJ, Meijer JW, De Beer-Pawlikowski N, et al. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol. 1983;40(13):797–802.
   PubMedGoogle Scholar
• Czuczwar SJ, Kaplanski J, Swiderska-Dziewit G, et al. Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Drug Metab Toxicol. 2009;5(2):131–136.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 1997;26(3):423–432.
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet. 1998;351(9107):958–959.
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Forsyth M, Kelly K, et al. Antiepileptic drug combinations—Have newer agents altered clinical outcomes? Epilepsy Res. 2012;98(2–3):194–198.
   PubMed Web of Science ®Google Scholar
• Leach JP, Brodie MJ. Synergism with GABAergic drugs in refractory epilepsy. The Lancet. 1994;343(8913):1650.
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Ratnaraj N, Patsalos PN, et al. Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur J Pharmacol. 2008;595(1–3):13–21.
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Andres MM, Czuczwar P, et al. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia. 2006;47(1):10–20.
   PubMed Web of Science ®Google Scholar
• Klee R, Töllner K, Rankovic V, et al. Network pharmacology for antiepileptogenesis: tolerability of multitargeted drug combinations in nonepileptic vs. post-status epilepticus mice. Epilepsy Res. 2015;118:34–48.
   PubMed Web of Science ®Google Scholar
• Moavero R, Pisani LR, Pisani F, et al. Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf. 2018;17(10):1015–1028.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548–1554.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Sander JW, Privitera M, et al. Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy Behav. 2010;18(1–2):24–30.
   PubMed Web of Science ®Google Scholar
• St Louis EK. Truly “Rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol. 2009;7(2):96–105.
   PubMed Web of Science ®Google Scholar
• Li MCH, Cook MJ. Deep brain stimulation for drug-resistant epilepsy. Epilepsia. 2018;59(2):273–290.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000;9(7):464–468.
   PubMed Web of Science ®Google Scholar
• Abou-Khalil B. Selecting rational drug combinations in epilepsy. CNS Drugs. 2017;31(10):835–844.
   PubMed Web of Science ®Google Scholar
• Jonker DM, Voskuyl RA, Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia. 2007;48(3):412–434.
   PubMed Web of Science ®Google Scholar
• Naik GS, Kodagali R, Mathew BS, et al. Therapeutic drug monitoring of levetiracetam and lamotrigine: is there a need? Ther Drug Monit. 2015;37(4):437–444.
   PubMed Web of Science ®Google Scholar
• Piskorska B, Miziak B, Czuczwar SJ, et al. Safety issues around misuse of antiepileptics. Expert Opin Drug Saf. 2013;12(5):647–657.
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002;11(6):349–351.
   PubMed Web of Science ®Google Scholar
• Blaszczyk B, Miziak B, Czuczwar P, et al. A viewpoint on rational and irrational fixed-drug combinations. Exp Rev Clin Pharmacol. 2018;11(8):761–771.
   PubMed Web of Science ®Google Scholar
• Hilgers A, Schaefer M. Systematic adverse drug reaction monitoring of patients under newer antiepileptic drugs using routine clinical data of inpatients. Drugs - Real World Outcomes. 2016;3(2):209–221.
   PubMedGoogle Scholar
• Deckers CLP, Genton P, Sills GJ, et al. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res. 2003;53(1–2):1–17.
   PubMed Web of Science ®Google Scholar
• Schmidt D. Drug treatment strategies for epilepsy revisited: starting early or late? One drug or several drugs? Epileptic Disord. 2016;18(4):356–366.
   PubMed Web of Science ®Google Scholar